{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:47:11Z","timestamp":1772772431301,"version":"3.50.1"},"reference-count":156,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2018,11,2]]},"DOI":"10.1080\/03007995.2018.1467885","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T12:54:04Z","timestamp":1524142444000},"page":"1945-1957","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban"],"prefix":"10.1080","volume":"34","author":[{"given":"A. John","family":"Camm","sequence":"first","affiliation":[{"name":",","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A. A.","family":"Fox","sequence":"additional","affiliation":[{"name":",","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,5,21]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.069492"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE2008021"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S53420"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2007.09.002"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs253"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.09.017"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182742c84"},{"key":"e_1_3_3_11_1","first-page":"2569","article-title":"ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the","volume":"33","author":"Steg PG","year":"2012","unstructured":"Steg PG, James SK, Atar D, et\u00a0al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33:2569-619","journal-title":"European Society of Cardiology (ESC). Eur Heart J"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2306"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12083"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360403"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90409-T"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60245-8"},{"key":"e_1_3_3_23_1","unstructured":"Janssen Pharmaceuticals Inc. Xarelto (Rivaroxaban) Prescribing Information. Titusville NJ USA 2017. Available at: http:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf [Last accessed 7 December 2017]"},{"key":"e_1_3_3_24_1","unstructured":"Bayer AG. Xarelto (Rivaroxaban) Summary of Product Characteristics. Berlin Germany 2018. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf [Last accessed 21 March 2018]"},{"key":"e_1_3_3_25_1","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Pradaxa (Dabigatran Etexilate) Prescribing Information. Ridgefield CT USA 2018. Available at: http:\/\/bidocs.boehringer-ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing%20Information\/PIs\/Pradaxa\/Pradaxa.pdf [Last accessed 28 March 2018]"},{"key":"e_1_3_3_26_1","unstructured":"Boehringer Ingelheim International GmbH. Pradaxa (Dabigatran Etexilate) Summary of Product Characteristics. Ingelheim am Rhein Germany 2017. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf [Last accessed 21 March 2018]"},{"key":"e_1_3_3_27_1","unstructured":"Bristol-Myers Squibb Company Pfizer Inc. Eliquis (Apixaban) Prescribing Information. Princeton NJ USA 2018. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf [Last accessed 7 December 2017]"},{"key":"e_1_3_3_28_1","unstructured":"Bristol-Myers Squibb Pfizer. Eliquis (Apixaban) Summary of Product Characteristics. Uxbridge UK 2017. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf [Last accessed 21 March 2018]"},{"key":"e_1_3_3_29_1","unstructured":"Daiichi Sankyo Inc. Savaysa (Edoxaban) Prescribing Information. Parsippany NJ USA 2017. Available at: http:\/\/dsi.com\/prescribing-information-portlet\/getPIContent?productName=Savaysa&inline=true [Last accessed 7 December 2017]"},{"key":"e_1_3_3_30_1","unstructured":"Daiichi Sankyo Europe GmbH. Lixiana (Edoxaban) Summary of Product Characteristics. Munich Germany 2017. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf [Last accessed 21 March 2018]"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/2048872614554109"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.03.022"},{"key":"e_1_3_3_33_1","unstructured":"National Institute for Health and Care Excellence. Atrial fibrillation: management. Clinical guideline [CG180]. Updated 2014. Available at: https:\/\/www.nice.org.uk\/guidance\/cg180 [Last accessed 24 May 2017]"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2304"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"e_1_3_3_36_1","first-page":"1114","article-title":"2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can","volume":"30","author":"Verma A","year":"2014","unstructured":"Verma A, Cairns JA, Mitchell LB, et\u00a0al. 2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation. Can J Cardiol 2014;30:1114-30","journal-title":"J Cardiol"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.08.032"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.03.020"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.01.031"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.012061"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12391"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv466"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563577"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-06-0484"},{"issue":"2","key":"e_1_3_3_45_1","first-page":"35","article-title":"Real life efficacy and safety of apixaban for stroke prevention in atrial fibrillation \u2013 results of the prospective NOAC registry (NCT01588119)","volume":"13","author":"Beyer-Westendorf J","year":"2015","unstructured":"Beyer-Westendorf J, Werth S, Tittl L, et\u00a0al. Real life efficacy and safety of apixaban for stroke prevention in atrial fibrillation \u2013 results of the prospective NOAC registry (NCT01588119). J Thromb Haemost 2015;13(Suppl S2):35 Abstract AS098","journal-title":"J Thromb Haemost"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.09.037"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.933577"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.907140"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcac.2015.06.007"},{"issue":"2","key":"e_1_3_3_50_1","first-page":"139","article-title":"Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF","volume":"13","author":"Kakkar AK","year":"2015","unstructured":"Kakkar AK, Accetta G, Agnelli G, et\u00a0al. Risk profiles and 1-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. J Thromb Haemost 2015;13(Suppl 2):139 Abstract OR119","journal-title":"J Thromb Haemost"},{"key":"e_1_3_3_51_1","unstructured":"Camm AJ Ambrosio G Atar D et\u00a0al. Patterns of uptake of non-vitamin K antagonist oral anticoagulants in Europe: an analysis from the GARFIELD-AF registry. Presented at: European Society of Cardiology Congress London UK 28 August\u20132 September 2015"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-02-0116"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.07.013"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-10-0840"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22373"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-03-0247"},{"key":"e_1_3_3_57_1","first-page":"253","article-title":"Real-world evidence on stroke prevention in patients with atrial fibrillation in the United States: the REVISIT-US study","volume":"45","author":"Coleman C","year":"2016","unstructured":"Coleman C, Antz M, Simard E, et\u00a0al. Real-world evidence on stroke prevention in patients with atrial fibrillation in the United States: the REVISIT-US study. J Interv Cardiac Electrophysiol 2016;45:253-4 Abstract 15-48","journal-title":"J Interv Cardiac Electrophysiol"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.07.024"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1857"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1585"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.001798"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5398"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-06-0453"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1131676"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-309832"},{"key":"e_1_3_3_66_1","unstructured":"Camm AJ Ambrosio G Atar D et\u00a0al. Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in GARFIELD-AF. Presented at: European Society of Cardiology Congress London UK 28 August\u20132 September 2015"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000349"},{"key":"e_1_3_3_68_1","unstructured":"Granger CB. Is there a role for pharmacokinetic\/pharmacodynamics guided dosing for novel anticoagulants? Presented at: Cardiac Safety Research Consortium Scientific Meeting 3 December 2015"},{"key":"e_1_3_3_69_1","unstructured":"Yao X Shah ND Sangaralingham LR et\u00a0al. Effectiveness and safety of reduced dose NOACs in patients without severe renal impairment. Presented at: International Society For Pharmacoeconomics and Outcomes Research 21st Annual International Meeting Washington DC USA 21-25 May 2016"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv421"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1074064"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1077213"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.09.023"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv309"},{"key":"e_1_3_3_76_1","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1","author":"Diener HC","year":"2017","unstructured":"Diener HC, Aisenberg J, Ansell J, et\u00a0al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J 2017;38:852-9","journal-title":"Eur Heart J"},{"key":"e_1_3_3_77_1","article-title":"Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2","author":"Diener HC","year":"2017","unstructured":"Diener HC, Aisenberg J, Ansell J, et\u00a0al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J 2017;38:860-8","journal-title":"Eur Heart J"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000120509.64740.DC"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2005.071860"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2014.12.009"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.025"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.977546"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.09.062"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu367"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.12.024"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31474-X"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.937953"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy176"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006426"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2011.12.016"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.039"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.114.001586"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/pace.12401"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.4022\/jafib.1634"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv177"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205512"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109719"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112277"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi485"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105819"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr113"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30751-1"},{"key":"e_1_3_3_107_1","first-page":"1255","volume-title":"J Am Geriatr Soc","author":"Ness J","year":"1999","unstructured":"Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999;47:1255-6"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.5.1472"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.2147\/vhrm.s32229"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202063260605"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn534"},{"key":"e_1_3_3_112_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065959"},{"key":"e_1_3_3_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02776-6"},{"key":"e_1_3_3_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709118"},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32409-1"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2014.11.001"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v7.i7.397"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2000.111108"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.986661"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu008"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.271"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl488"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.06.004"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62177-1"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.114967"},{"key":"e_1_3_3_126_1","first-page":"1311","article-title":"Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing coronary stenting: executive summary \u2013 a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart","volume":"31","author":"Lip GYH","year":"2010","unstructured":"Lip GYH, Huber K, Andreotti F, et\u00a0al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing coronary stenting: executive summary \u2013 a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010;31:1311-18","journal-title":"J"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611594"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708454"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfs105"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.266"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.12.14"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70310-7"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311376"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.03.032"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313600"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32458-3"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.2217\/fca.13.109"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv115"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1111\/jce.12864"},{"key":"e_1_3_3_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2013.10.007"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.3180"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.003989"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.15192"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.04.025"},{"key":"e_1_3_3_145_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu365"},{"key":"e_1_3_3_146_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu352"},{"key":"e_1_3_3_148_1","unstructured":"World Heart Federation. Launch of biggest ever rheumatic heart disease patient programme. 2016. Available at: https:\/\/www.world-heart-federation.org\/wp-content\/uploads\/2017\/05\/Invictus_Trial_launch_07.06.16.pdf [Last accessed 29 March 2018]"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2305"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315581207"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315611495"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs274"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022361"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014554446"},{"key":"e_1_3_3_155_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.628"},{"key":"e_1_3_3_156_1","doi-asserted-by":"publisher","DOI":"10.1159\/000445328"},{"key":"e_1_3_3_157_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001573"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2018.1467885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T09:24:21Z","timestamp":1770369861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2018.1467885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,21]]},"references-count":156,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,2]]}},"alternative-id":["10.1080\/03007995.2018.1467885"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2018.1467885","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}